Drugs.com - New Drug Approvals

FDA Grants Isturisa (osilodrostat) Expanded Indication for the Treatment of Endogenous Hypercortisolemia in Patients with Cushing’s Syndrome

Milan, Italy and Bridgewater, NJ, April 16, 2025 – Today Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous...

Apr 23, 2025 - 01:03
 0
FDA Grants Isturisa (osilodrostat) Expanded Indication for the Treatment of Endogenous Hypercortisolemia in Patients with Cushing’s Syndrome
Milan, Italy and Bridgewater, NJ, April 16, 2025 – Today Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous...
Read More

Tags:

Previous Article

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluati...

Next Article

Trade unionists, conservationists and church groups unite against Dutton’s nucle...

Related Posts

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

FDA Approves Genentech’s Evrysdi Tablet as First and On...

Feb 13, 2025  0

U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

U.S. Food and Drug Administration Updates Camzyos (mava...

Apr 22, 2025  0

Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease

Uplizna (inebilizumab-cdon) is Now the First and Only F...

Apr 14, 2025  0